Rocket Pharmaceuticals
RCKT
147 hedge funds and large institutions have $892M invested in Rocket Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 40 reducing their positions, and 22 closing their positions.
160% more call options, than puts
Call options by funds: $848K | Put options by funds: $326K
50% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 40
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
2% more capital inflows, than outflows
Capital inflows: $70.4M | Capital outflows: $69.2M
1% less funds holding
Funds holding: 149 → 147 (-2)
1.39% less ownership
Funds ownership: 99.81% → 98.41% (-1.4%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$13.8M |
| 2 |
BlackRock
New York
|
+$8.04M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$5.92M |
| 4 |
Maverick Capital
Dallas,
Texas
|
+$4.76M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.16M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$6.21M |
| 4 |
Perceptive Advisors
New York
|
-$6.09M |
| 5 |
Barclays
London,
United Kingdom
|
-$4.63M |
RCKT Hedge Fund Activity: Q2 2022 in Review
147 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2022, worth a combined $892M — down 14% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RCKT positions and 22 closed out — a net gain of 1 holder — while 60 added to existing stakes and 40 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $13.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $13.1M.
- 147 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2022, down from 149 in Q1 2022.
- Funds reported $892M of Rocket Pharmaceuticals stock for Q2 2022, down 14% quarter-over-quarter.
- 23 funds opened new Rocket Pharmaceuticals positions in Q2 2022 and 22 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals buyer in Q2 2022 was Westfield Capital Management, an estimated $13.8M added.
- The largest Rocket Pharmaceuticals seller in Q2 2022 was T. Rowe Price Associates, an estimated $13.1M sold.
Based on aggregated 13F filings for Q2 2022.